|Reactivity||Human, Mouse, Rat|
|Calculated MW||71330 Da|
|Homology||Mouse, rat - 12/13 amino acid residues identical.|
|Other Names||Potassium voltage-gated channel subfamily D member 1, Voltage-gated potassium channel subunit Kv41, KCND1|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)KRRAIRLANSTAS, corresponding to amino acid residues 538-550 of human Kv4.1 (Accession Q9NSA2 ). Intracellular, C-terminal domain.|
|Peptide Confirmation||Confirmed by amino acid analysis and massspectrography.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.6 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.025% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kv4.1 is a voltage-dependent K+ channel that belongs to the Shal channel subfamily and includes two other members: Kv4.2 and Kv4.3. Kv4.1 possesses the signature structure of the voltage-dependent K+ channels: six membrane-spanning domains with intracellular N and C termini. As with other members of the voltage-gated K+ channel superfamily, the functional channel is a tetramer that can be composed of more than one member of the Shal subfamily, i.e. heterotetramers of Kv4.1 and Kv4.2. The Kv4 channels are characterized by activation at subthreshold membrane potentials, inactivate rapidly and recover from inactivation quickly compared with other voltage-dependent K+ channels. This type of current is known as transient A-type K+ currents. For example, depolarization-activated K+ currents in rat neostriatal cholinergic interneurons are predominantly of the A-type and attributable to coexpression of Kv4.1 and Kv4.2 subunits. The biophysical properties of the Kv4.1 subunit can be modified by its association with auxiliary b subunits such as KChIP1 that increase Kv4.1 current densities and accelerates both the inactivation and the recovery time. Kv4.1 is highly expressed in brain but is also expressed in peripheral tissues such as colon, heart and lung. The pharmacology of Kv4.1 has been less well studied than that of the other Kv4 members. Kv4.1 is sensitive to the classical K+ channel blockers, 4-aminopyridine and tetraethylammonium. Recently HmTx1 a peptide blocker derived from the venom of the African tarantula Heteroscodra maculata has been shown to be a potent inhibitor of Kv4.1. Abgent is pleased to offer a highly specific antibody directed against an intracellular epitope of human Kv4.1. The Anti-Kv4.1 antibody (#AG1094) can be used for western blot, immunohistochemistry and immunocytochemistry applications. It has been designed to recognize Kv4.1 from rat, human and mouse samples.
References 1. Pak, M.D. et al. (1991) Proc. Natl. Acad. Sci. 88, 4386. 2. Song, W.J. et al. (1998) J. Neurosci. 18, 3124. 3. Escoubas, P. et al. (2002) Mol. Pharmacol. 62, 48. 4. Birnbaum, S. et al. (2004) Physiol. Rev. 84, 803.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.